Table 1.
Patients and provider characteristics
| |
Breast cancer |
Carboplatin-treated lung cancer |
Cisplatin-treated lung cancer |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | |
| N |
3,606 |
1,742 |
1,864 |
|
4,497 |
2,691 |
1,806 |
|
1,154 |
764 |
390 |
|
|
Age mean (SD) |
53.7 (9.8) |
53.7 (9.7) |
53.7 (10.0) |
NS |
64.9 (10.2) |
64.77 (10.2) |
65.03 (10.3) |
NS |
60.5 (9.8) |
60.1 (9.8) |
61.3 (9.8) |
0.0476 |
|
CCI mean (SD) |
0.5 (1.0) |
0.5 (1.1) |
0.5 (1.0) |
NS |
6.8 (3.2) |
6.87 (3.2) |
6.71 (3.2) |
NS |
6.5 (3.3) |
6.6 (3.3) |
6.3 (3.2) |
NS |
|
Female, N (%) |
- |
- |
- |
- |
2,080 (46.3) |
1,258 (46.8) |
822 (45.5) |
NS |
459 (39.8) |
329 (43.1) |
130 (33.3) |
0.0014 |
|
Year of 5-HT3RA initiated |
|
|
|
<0.0001 |
|
|
|
<0.0001 |
|
|
|
NS |
| 2005 |
1,428 (39.6) |
753 (43.3) |
675 (36.2) |
|
1,562 (34.7) |
990 (36.8) |
572 (31.7) |
|
348 (30.2) |
247 (32.3) |
101 (25.9) |
|
| 2006 |
1,537 (42.6) |
720 (41.3) |
817 (43.8) |
|
1,480 (32.9) |
857 (31.9) |
623 (34.5) |
|
394 (34.1) |
263 (34.4) |
131 (33.6) |
|
| 2007 |
520 (14.4) |
223 (12.8) |
297 (15.9) |
|
1,140 (25.4) |
687 (25.5) |
453 (25.1) |
|
315 (27.3) |
194 (25.4) |
121 (31.0) |
|
| 2008 | 121 (3.4) | 46 (2.6) | 75 (4.0) | 315 (7.0) | 157 (5.8) | 158 (8.8) | 97 (8.4) | 60 (7.9) | 37 (9.5) | |||
P: P value; CCI: Charlson Comorbidity Index; 5-HT3 RAs: 5-hydroxytryptamine receptor antagonists.